S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
This Skill Could Change The Way You Trade! (Ad)pixel
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
The single greatest medical breakthrough of all time? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
NASDAQ:TPTX

Turning Point Therapeutics - TPTX Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$76.01
$76.01
50-Day Range
$74.80
$76.01
52-Week Range
$23.77
$82.20
Volume
4,322 shs
Average Volume
1.14 million shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.22

Turning Point Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
2.9% Upside
$78.22 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($7.69) to ($8.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.63 out of 5 stars

Medical Sector

1033rd out of 1,034 stocks

Pharmaceutical Preparations Industry

501st out of 502 stocks

TPTX stock logo

About Turning Point Therapeutics (NASDAQ:TPTX) Stock

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPTX Stock News Headlines

The Energy Report: Turning Point
The Ukraine war has reached a turning point
Analyst Ratings for Turning Point
Expert Ratings for Turning Point
See More Headlines

Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPTX Company Calendar

Last Earnings
11/09/2021
Today
12/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TPTX
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.22
High Stock Price Forecast
$116.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
+2.9%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-236,550,000.00
Pretax Margin
-33,959.03%

Debt

Sales & Book Value

Annual Sales
$30.83 million
Book Value
$15.84 per share

Miscellaneous

Free Float
45,768,000
Market Cap
$3.81 billion
Optionable
Not Optionable
Beta
-0.18

Key Executives

  • Dr. Athena Maria Countouriotis M.D. (Age 50)
    Pres, CEO & Director
    Comp: $1.19M
  • Mr. Paolo TombesiMr. Paolo Tombesi (Age 58)
    Exec. VP & CFO
    Comp: $741.19k
  • Dr. Mohammad HirmandDr. Mohammad Hirmand (Age 52)
    Exec. VP & Chief Medical Officer
    Comp: $783.77k
  • Mr. Ed Gemo
    Sr. VP & Chief Information Officer
  • Dr. Gavin Hirst Ph.D.
    Sr. VP of Chemistry & Interim Chief Scientific Officer
  • Dr. Adam D. Levy M.B.A.
    Ph.D., Sr. VP of Investor Relations & Corp. Communications
  • Mr. Raymond J. Furey J.D. (Age 54)
    Sr. VP & Chief Compliance Officer
  • Mr. Brian Sun J.D. (Age 38)
    M.S., Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Heather Adams
    Sr. VP of HR
  • Dr. Jeffrey P. Whitten
    Sr. VP of Pre-Clinical Devel.













TPTX Stock - Frequently Asked Questions

Should I buy or sell Turning Point Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TPTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TPTX, but not buy additional shares or sell existing shares.
View TPTX analyst ratings
or view top-rated stocks.

What is Turning Point Therapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued 12-month price targets for Turning Point Therapeutics' stock. Their TPTX share price forecasts range from $45.00 to $116.00. On average, they anticipate the company's stock price to reach $78.22 in the next twelve months. This suggests a possible upside of 2.9% from the stock's current price.
View analysts price targets for TPTX
or view top-rated stocks among Wall Street analysts.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by $0.08. The company earned $0.46 million during the quarter. During the same period in the prior year, the business posted ($0.42) EPS.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GSK (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TIG Advisors LLC (0.00%), Citadel Advisors LLC (0.00%), Centiva Capital LP (0.00%), Ramius Advisors LLC (0.00%), Picton Mahoney Asset Management (0.00%) and Clear Street Markets LLC (0.00%). Insiders that own company stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Paolo Tombesi, Siegfried Reich and Yi Larson.
View institutional ownership trends
.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $76.01.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics (NASDAQ:TPTX) has a market capitalization of $3.81 billion and generates $30.83 million in revenue each year. The company earns $-236,550,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

The company employs 250 workers across the globe.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.tptherapeutics.com. The company can be reached via phone at (858) 926-5251 or via email at jim.mazzola@tptherapeutics.com.

This page (NASDAQ:TPTX) was last updated on 12/4/2022 by MarketBeat.com Staff